Form 4: Akebia Therapeutics Director Myles Wolf Receives Stock Options and Restricted Stock Units

Director Myles Wolf acquired 30,000 shares of common stock and stock options for 45,000 shares of Akebia Therapeutics.

Summary

• Myles Wolf, a director of Akebia Therapeutics, acquired 30,000 shares of common stock on June 6, 2024, at a price of $0.00.
• Wolf also acquired stock options for 45,000 shares of common stock with an exercise price of $1.07, also on June 6, 2024.
• The restricted stock units (RSUs) and stock options were granted pursuant to the company's 2023 Stock Incentive Plan and the Third Amended and Restated Non-Employee Director Compensation Program.
• The RSUs and stock options will vest in full on the first anniversary of the grant date or earlier if the first annual meeting of stockholders occurs before that date, contingent upon continued service to the Issuer.
• Following the transaction, Wolf directly owns 97,681 shares of Akebia Therapeutics common stock and options for 45,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard director compensation practices, which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

Stock grants and options are a common form of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing company performance.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are standard practice among publicly traded biotechnology companies like Akebia Therapeutics.
• Companies such as Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation plans for their board members to align their interests with long-term shareholder value.
• The vesting schedules, typically one year, are also in line with industry norms to ensure continued service and commitment from directors.

Stakeholder Impact

• The stock grants and options align the director's interests with those of the shareholders, potentially leading to decisions that benefit shareholder value.
• The vesting schedule incentivizes the director's continued service to the company.

Key Dates